嘉事堂(002462) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was CNY 6,460,665,483.96, representing an increase of 11.19% compared to CNY 5,810,550,826.94 in the same period last year[3] - Net profit attributable to shareholders decreased by 3.65% to CNY 78,838,414.53 from CNY 81,829,097.05 year-on-year[3] - The company's net profit for Q1 2022 was RMB 167,149,109.01, a decrease from RMB 199,285,946.50 in the previous year, indicating a decline of 16.14%[16] - The total revenue for the first quarter was approximately CNY 6.76 billion, a slight decrease from CNY 6.82 billion in the previous year, representing a decline of about 0.95%[19] - The net profit for the first quarter was CNY 121.40 million, down from CNY 144.89 million year-over-year, indicating a decrease of approximately 16.16%[19] Cash Flow and Liquidity - The net cash flow from operating activities was negative at CNY -681,528,106.88, a decline of 415.95% compared to CNY 215,705,560.04 in the previous year[3] - The cash flow from operating activities showed a net outflow of CNY 681.53 million, compared to a net inflow of CNY 215.71 million in the same period last year[19] - Cash and cash equivalents at the end of Q1 2022 were RMB 1,905,282,390.45, down from RMB 2,338,121,461.75 at the beginning of the year, representing a decrease of 18.56%[12] - The company reported a cash and cash equivalents balance of CNY 1.75 billion at the end of the quarter, down from CNY 1.55 billion at the end of the previous year[21] - The company raised CNY 1.23 billion through borrowings, significantly higher than CNY 456 million in the same period last year, indicating a strong financing activity[21] - The total cash inflow from financing activities was CNY 1.28 billion, compared to CNY 489.51 million in the previous year, showing a substantial increase[21] - The company incurred a cash outflow of CNY 970.07 million for debt repayment, which is slightly higher than CNY 929.91 million in the previous year[21] - The net cash flow from investing activities was negative at CNY 6.44 million, worsening from a negative CNY 4.31 million in the previous year[21] Assets and Liabilities - Total assets increased by 2.68% to CNY 15,337,191,397.86 from CNY 14,937,549,976.72 at the end of the previous year[3] - Total liabilities increased to RMB 9,585,873,663.72 from RMB 9,280,992,337.21, indicating a rise of 3.28%[14] - The company's equity attributable to shareholders reached RMB 3,966,293,521.25, up from RMB 3,886,549,170.39, reflecting an increase of 2.05%[14] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 25,744[9] - The top shareholder, China Everbright Medical Health Industry Co., Ltd., holds 14.36% of the shares, totaling 41,876,431 shares[9] Operational Insights - Total operating costs for Q1 2022 were RMB 6,301,531,573.16, up from RMB 5,636,858,890.89, reflecting a year-over-year increase of 11.74%[16] - The company did not report any new product developments or market expansion strategies in this quarter[3] - Research and development expenses for Q1 2022 were RMB 863,217.54, indicating ongoing investment in innovation[16] - The company reported a significant decrease in the disposal of assets, with asset disposal income dropping by 92.1% to CNY 27,897.69[6] - The company did not report any net profit from subsidiaries under common control during the quarter, consistent with the previous year[18] Inventory and Receivables - Accounts receivable increased to RMB 8,128,526,887.18 from RMB 7,787,339,611.18, marking a rise of 4.39%[12] - Inventory at the end of Q1 2022 was RMB 2,425,479,882.35, up from RMB 2,185,383,123.69, reflecting an increase of 11.01%[12]